Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Treatment Boosts Cancer Vaccine

01.04.2003


The first clinical trials of a new type of cancer treatment that releases the “brakes” on immune cells indicate that this approach enhances attacks on tumors while sparing the body’s own tissue.

The results of the phase I clinical trials of cytotoxic T-lymphocyte-associated antigen 4 blockade therapy were published online on April 1, 2003, in the Early Edition of the Proceedings of the National Academy of Sciences. The researchers involved in the study included James Allison, a Howard Hughes Medical Institute investigator at the University of California, Berkeley, Glenn Dranoff, Steven Hodi and colleagues from the Dana-Farber Cancer Institute (DFCI), Brigham and Women’s Hospital, Massachusetts General Hospital and Harvard Medical School.

Over the last decade, basic research in Allison’s laboratory and others has shown that the immune-regulating molecule, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), inhibits activated immune system T cells, and prevents them from attacking the body’s own tissues. In studies in mice, Allison and his colleagues identified an antibody that blocks CTLA-4 and showed that it enhances the cancer-fighting activity of certain anti-cancer vaccines. Their research showed that blocking CTLA-4 maintains the response of T cells triggered by the vaccines to attack the cancer.



The success of the experiments in mice prompted the researchers to begin initial clinical studies to test whether they could elicit the same kind of response in humans. The phase I clinical trial — which aimed primarily at establishing the safety of the treatment — included nine patients with advanced cancers who had previously received cancer vaccines.

Three of the patients with metastatic melanoma and two with ovarian cancer had received a vaccine produced by extracting their own cancer cells, engineering the cells to produce the immune-stimulating molecule, granulocyte-macrophage-colony-stimulating factor (GM-CSF), and vaccinating the patients with those cells. This vaccine was developed by Dranoff and his colleagues at DFCI. Four other metastatic melanoma patients had received different vaccines based on immune-stimulating antigens specific to melanomas.

Although the five patients treated with the GM-CSF vaccine had not responded completely to that vaccine, the researchers found clear evidence that the anti-CTLA-4 antibody enhanced the immune system attack on their tumors. However, treatment with the antibodies did not enhance tumor killing in the four melanoma patients treated with the melanoma antigens.

“In the melanoma patients who responded to the anti-CTLA-4 treatment, Dr. Dranoff saw a skin rash, which is a positive reaction,” said Allison. “Such rashes are evidence that the T cells were attacking normal melanocytes in the skin, which is considered a good prognostic sign for people with melanoma. It indicates that the melanoma is being attacked as well. And while the tumor size did not necessarily immediately decrease in these patients, it was clear from pathology studies that tumor cells were being killed and being replaced by these inflammatory T cells.” According to Allison, the patients with ovarian cancer showed an increase in the bloodstream of a marker molecule indicating that the cancer cells were being killed.

Other clinical trials of the anti-CTLA-4 antibody are ongoing, said Allison, and the early results from all the trials make him optimistic that the treatment will prove highly useful. “In my opinion, what is most exciting is that there is no reason that this approach to tumor therapy is limited to any particular kind of cancer,” he said. “However, until we get more experience with the treatment, we should take extreme care before extending CTLA-4 blockade from cancers arising from tissues that are not absolutely essential.”

According to Allison, CTLA-4 blockade could boost anti-cancer immune response to aid several kinds of therapies. “We have preliminary data indicating that the treatment can synergize not only with immunotherapy, but also with radiation and chemotherapy,” he said. “Under circumstances where these treatments also activate the immune system, anti-CTLA-4 therapy could enhance those therapies.”

Allison emphasized that the anti-CTLA-4 antibodies only stimulate the immune system during a narrow window of treatment. “The beauty of this treatment is that the antibodies by themselves are benign. After they clear from the system, immune regulation returns to normal, and the patient is left with an amplified population of anti-tumor T cells.”

Jim Keeley | Howard Hughes Medical Institute
Further information:
http://www.hhmi.org/

More articles from Health and Medicine:

nachricht Cholesterol-lowering drugs may fight infectious disease
22.08.2017 | Duke University

nachricht Once invincible superbug squashed by 'superteam' of antibiotics
22.08.2017 | University at Buffalo

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

What the world's tiniest 'monster truck' reveals

23.08.2017 | Life Sciences

Treating arthritis with algae

23.08.2017 | Life Sciences

Witnessing turbulent motion in the atmosphere of a distant star

23.08.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>